SAN DIEGO, CA, Feb. 25, 2014 /PRNewswire/ -- Suneva Medical, Inc., a privately-held aesthetics company, today announced the results of a third-party study which examined consumer preferences of Regenica® Overnight Repair (Regenica®) relative to SkinMedica's TNS Essential Serum® (TNS®). The blinded, split-face study, conducted by global independent science safety company, UL, revealed that nearly twice as many users preferred Regenica® overall. The study, which included women between the ages of 35 and 60, determined that 79% of consumers preferred the smell of Regenica® to TNS® and they reported increased radiance, smoother texture, and a more even and rejuvenated skin tone. Additionally, 76% of study participants reported that they would recommend Regenica® to a friend.
"TNS® brought growth factors into the mainstream a decade ago," commented Nicholas L. Teti, Jr., Chairman and Chief Executive Officer of Suneva Medical. "Regenica® represents the latest in growth factor technology. The study clearly evaluates the key attributes consumers look for in skincare products and we are pleased that Regenica® excelled."
The Regenica® skincare line is distributed by Suneva Medical. Suneva Medical also has a co-promotion agreement with Obagi Medical Products, Inc. to distribute Regenica® in the U.S. The product line is exclusively dispensed through physician offices and is available for purchase in dermatology, plastic surgery and other physician practices.
About Suneva Medical, Inc.
Suneva Medical, Inc. is a privately-held aesthetics company focused on developing, manufacturing and commercializing novel, differentiated products for the general dermatology and aesthetic markets. The company currently markets ArteFill® in the US, Korea and Singapore; ReFissa® and Regenica® in the U.S. and Bellafill® in Canada. For more information, visit www.sunevamedical.com.
TNS® and TNS Essential Serum® are registered trademarks of Allergan, Inc.
Regenica® is manufactured under U.S. Patent No. 8,524,494.
SOURCE Suneva Medical, Inc.